Secukinumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Secukinumab |
| DrugBank ID | DB09029 |
| Brand Names (EU) | Cosentyx |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.16% |
Approved Indication (EMA)
Plaque psoriasis Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. Hidradenitis suppurativa (HS) Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. Psoriatic arthritis Cosentyx, alone or in combination with methotrexate (MTX), is indicated for th
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary release disorder of platelets | 98.16% | DL |
| 2 | pseudo-von Willebrand disease | 97.74% | DL |
| 3 | Glanzmann thrombasthenia | 97.34% | DL |
| 4 | HER2 positive breast carcinoma | 96.48% | DL |
| 5 | drug-induced osteoporosis | 95.27% | DL |
| 6 | progesterone-receptor positive breast cancer | 95.09% | DL |
| 7 | normal breast-like subtype of breast carcinoma | 95.09% | DL |
| 8 | breast tumor luminal A or B | 94.98% | DL |
| 9 | progesterone-receptor negative breast cancer | 94.51% | DL |
| 10 | fetal and neonatal alloimmune thrombocytopenia | 92.69% | DL |
| 11 | ankylosing spondylitis | 92.28% | DL |
| 12 | autosomal dominant macrothrombocytopenia | 92.05% | DL |
| 13 | rheumatoid vasculitis | 91.25% | DL |
| 14 | inflammatory spondylopathy | 91.04% | DL |
| 15 | chromhidrosis | 90.72% | DL |
| 16 | hypermobility of coccyx | 90.65% | DL |
| 17 | Kummell disease | 90.06% | DL |
| 18 | polyarticular juvenile rheumatoid arthritis | 89.35% | DL |
| 19 | hidradenitis | 88.14% | DL |
| 20 | Crohn’s colitis | 86.82% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.